CVR: 38180045
Secondary names: Novo Nordisk Region Europe Pharmaceuticals A/S, Novo Nordisk North West Europe Pharmaceuticals A/S
Previous names: Novo Nordisk Region Europe Pharmaceuticals A/S
Novo Nordisk Denmark A/S is a Danish company of the type Aktieselskab based in København S, founded in 2016. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named Novo Nordisk Region Europe Pharmaceuticals A/S. The management consists of Mads Wilhelm Øckenholt Larsen. The company is owned by NOVO NORDISK REGION EUROPE A/S. The company has 81 employees. In 2025, the company reported revenue of DKK 2,504,841,000 and a net result of DKK 118,803,000 compared with DKK 86,129,000 the year before. Equity amounted to DKK 134,570,000.
Novo Nordisk Denmark A/S demonstrates a strong upward trajectory in financial health, with revenue increasing significantly from 373.9 million DKK in 2021 to 2.5 billion DKK in 2025. Profitability has also improved, with profits rising from 21.4 million DKK in 2021 to 118.8 million DKK in 2025, indicating enhanced operational efficiency and market demand. The company's equity has nearly tripled over the same period, reaching 134.6 million DKK, which reflects a solid financial foundation. However, the rapid growth raises potential concerns regarding sustainability and market competition within the pharmaceutical wholesale sector. Overall, Novo Nordisk is well-positioned in its industry, benefiting from strong revenue growth and improving profit margins.
AI-generated summary
Your company? Claim the profile and show your logo, website and social channels — for free.
Claim this profileSelskabets formål er at markedsføre, promovere, importere, sælge og distribuere farmaceutiske og medicinske produkter, repræsentation af selskaber, supporterende services og forretningsassistance til interessenter i Europa, rådgivning og services i forbindelse med registrering af farmaceutiske produkter, forskning og udvikling af farmaceutiske produkter, kliniske forsøg, samt anden hertil knyttet virksomhed der ikke er forbudt ved lov. Selskabets formål er tillige at understøtte Novo Nordisk A/S farmaceutiske aktivitet. Selskabet tilstræber at drive sin virksomhed på økonomisk, miljømæssigt og socialt ansvarlig vis.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 2.5 mia. | 118.8 mio. | 1.4 mia. | 134.6 mio. | 299 | |
| 2024 | 2.4 mia. | 86.1 mio. | 1.1 mia. | 101.8 mio. | 294 | |
| 2023 | 2 mia. | 82 mio. | 1.2 mia. | 97.6 mio. | 236 | |
| 2022 | 509.9 mio. | 33.5 mio. | 446.7 mio. | 49.1 mio. | 200 | |
| 2021 | 373.9 mio. | 21.4 mio. | 283.4 mio. | 37 mio. | 176 | |
| 2020 | 330.1 mio. | 21.3 mio. | 585 mio. | 36.6 mio. | 152 | |
| 2019 | 363.9 mio. | 5.3 mio. | 149.6 mio. | 15.3 mio. | 65 | |
| 2018 | 341.9 mio. | 4.2 mio. | 130 mio. | 10.1 mio. | 69 |
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringCompared to 412 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
1 public tender won
Sources: TED (the EU tender database) and udbud.dk
Novo Nordisk Denmark A/S has published its annual report for 2025. Revenue came to DKK 2,504,841,000, and the net result was DKK 118,803,000.
As of March 6, 2026, Jeppe Theisen has joined the board of directors of Novo Nordisk Denmark A/S.
As of March 6, 2026, David Marcus Svensson has joined the board of directors of Novo Nordisk Denmark A/S.
As of March 6, 2026, Malin Eva Maria Andreasen has left the board of directors of Novo Nordisk Denmark A/S.
As of March 6, 2026, Anders Rytter Mikkelsen has left the board of directors of Novo Nordisk Denmark A/S.
Novo Nordisk Denmark A/S has won the tender "Udbudsnummer 1" issued by Amgros I/S worth 103,180,000 DKK.
Novo Nordisk Denmark A/S has published its annual report for 2024. Revenue came to DKK 2,367,751,000, and the net result was DKK 86,129,000.
As of January 17, 2025, Mads Wilhelm Øckenholt Larsen is registered as director of Novo Nordisk Denmark A/S.
As of January 17, 2025, Jeppe Theisen has stepped down as director of Novo Nordisk Denmark A/S.
Novo Nordisk Denmark A/S has published its annual report for 2023. Revenue came to DKK 2,017,346,469, and the net result was DKK 81,997,613.
As of April 2, 2024, Malin Eva Maria Andreasen has joined the board of directors of Novo Nordisk Denmark A/S.
As of April 2, 2024, Anders Rytter Mikkelsen has joined the board of directors of Novo Nordisk Denmark A/S.
As of April 2, 2024, Tomas Haagen has left the board of directors of Novo Nordisk Denmark A/S.
As of April 2, 2024, Morten Berger Engelund has left the board of directors of Novo Nordisk Denmark A/S.
Novo Nordisk Denmark A/S has published its annual report for 2022. Revenue came to DKK 509,919,862, and the net result was DKK 33,547,904.
As of October 26, 2022, Jonas Emil Kongshøj Larsen has joined the board of directors of Novo Nordisk Denmark A/S.
As of October 26, 2022, Frederik Kier has left the board of directors of Novo Nordisk Denmark A/S.
As of October 26, 2022, Jeppe Theisen is registered as director of Novo Nordisk Denmark A/S.
As of October 26, 2022, Kasper Bødker Mejlvang has stepped down as director of Novo Nordisk Denmark A/S.
Novo Nordisk Denmark A/S has published its annual report for 2021. Revenue came to DKK 373,940,044, and the net result was DKK 21,405,179.
Novo Nordisk Denmark A/S has published its annual report for 2020. Revenue came to DKK 330,145,351, and the net result was DKK 21,277,960.
As of April 15, 2021, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Novo Nordisk Denmark A/S.
As of April 15, 2021, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of Novo Nordisk Denmark A/S.
Novo Nordisk Denmark A/S has published its annual report for 2019. Revenue came to DKK 363,935,809, and the net result was DKK 5,251,810.
As of April 1, 2020, Frederik Kier has joined the board of directors of Novo Nordisk Denmark A/S.
As of April 1, 2020, Morten Berger Engelund has joined the board of directors of Novo Nordisk Denmark A/S.
As of April 1, 2020, Mads Veggerby Lausten has left the board of directors of Novo Nordisk Denmark A/S.
As of April 1, 2020, Matt Joseph Regan has left the board of directors of Novo Nordisk Denmark A/S.
As of December 1, 2019, Kasper Bødker Mejlvang is registered as director of Novo Nordisk Denmark A/S.
As of November 30, 2019, Morten Berger Engelund has stepped down as director of Novo Nordisk Denmark A/S.
As of October 1, 2019, Mads Veggerby Lausten has joined the board of directors of Novo Nordisk Denmark A/S.
As of October 1, 2019, Matt Joseph Regan has joined the board of directors of Novo Nordisk Denmark A/S.
As of October 1, 2019, Karsten Munk Knudsen has left the board of directors of Novo Nordisk Denmark A/S.
On October 1, 2019, the company changed its name from Novo Nordisk Region Europe Pharmaceuticals A/S to Novo Nordisk Denmark A/S.
As of September 30, 2019, Matt Joseph Regan has left the board of directors of Novo Nordisk Denmark A/S.
Novo Nordisk Denmark A/S has published its annual report for 2018. Revenue came to DKK 341,939,236, and the net result was DKK 4,213,051.
As of October 1, 2018, Tomas Haagen has joined the board of directors of Novo Nordisk Denmark A/S.
As of October 1, 2018, Karsten Munk Knudsen has joined the board of directors of Novo Nordisk Denmark A/S.
As of October 1, 2018, Ole Falvig Ramsby has left the board of directors of Novo Nordisk Denmark A/S.
As of September 30, 2018, Karsten Munk Knudsen has left the board of directors of Novo Nordisk Denmark A/S.
As of May 15, 2018, Morten Berger Engelund is registered as director of Novo Nordisk Denmark A/S.
As of May 15, 2018, Steffen Hillebrandt Thejls has stepped down as director of Novo Nordisk Denmark A/S.
Novo Nordisk Denmark A/S has published its interim report for the period November 14, 2016 – December 31, 2017.
As of January 1, 2018, Steffen Hillebrandt Thejls is registered as director of Novo Nordisk Denmark A/S.
As of January 1, 2018, Mads Veggerby Lausten has stepped down as director of Novo Nordisk Denmark A/S.
As of September 15, 2017, Ole Falvig Ramsby has joined the board of directors of Novo Nordisk Denmark A/S.
As of September 15, 2017, Karsten Munk Knudsen has joined the board of directors of Novo Nordisk Denmark A/S.
As of September 15, 2017, Matt Joseph Regan has joined the board of directors of Novo Nordisk Denmark A/S.
As of September 15, 2017, Jesper Brandgaard has left the board of directors of Novo Nordisk Denmark A/S.
As of September 15, 2017, Lars Fruergaard Jørgensen has left the board of directors of Novo Nordisk Denmark A/S.
As of September 15, 2017, Karsten Munk Knudsen has stepped down as director of Novo Nordisk Denmark A/S.
As of September 14, 2017, Ole Falvig Ramsby has left the board of directors of Novo Nordisk Denmark A/S.
As of November 14, 2016, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Novo Nordisk Denmark A/S.
As of November 14, 2016, Ole Falvig Ramsby has joined the board of directors of Novo Nordisk Denmark A/S.
As of November 14, 2016, Jesper Brandgaard has joined the board of directors of Novo Nordisk Denmark A/S.
As of November 14, 2016, Lars Fruergaard Jørgensen has joined the board of directors of Novo Nordisk Denmark A/S.
As of November 14, 2016, Mads Veggerby Lausten is registered as director of Novo Nordisk Denmark A/S.
As of November 14, 2016, Karsten Munk Knudsen is registered as director of Novo Nordisk Denmark A/S.
As of November 14, 2016, NOVO NORDISK REGION EUROPE A/S is registered as an owner of Novo Nordisk Denmark A/S with an ownership share of 100%.
Novo Nordisk Denmark A/S was founded on November 14, 2016.
Companies in the same industry and area
CVR 41722460
CVR 39371049
CVR 39503778
CVR 40873309
CVR 31774284
companydata.dk